Advertisement
Organisation › Details
Otsuka Pharmaceutical Co., Ltd.
Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy, "Otsuka-people creating new products for better health worldwide." Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases, and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment. For more information, please visit www.otsuka.co.jp/en. About Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) is involved in conducting all phases of clinical research and development of innovative healthcare products to address unmet medical needs. OPDC is well established in the scientific community as a globally-focused organization that plays a leadership role in the research and development of Otsuka's ethical healthcare products. The company is dedicated to improving the quality of human life and patient health around the world with a strong commitment to research and development in the areas of neuroscience, cardiovascular diseases, and oncology. OPDC is part of the Otsuka Group companies. For more information, visit www.otsuka-us.com. OPDC is a subsidiary of Otsuka America, Inc., which is wholly owned by Otsuka Pharmaceutical Co., Ltd. *
Start | 1964-08-18 established | |
Group | Otsuka (Group) | |
Industry | pharmaceutical | |
Industry 2 | CNS drug (neurological drug) | |
City | 101-8241 Tokyo | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | H: 10,001 to 50,00 (2007-03-31) |
Currency | USD | |
Annual sales | 6,800,000,000 (sales (2005 fiscal)) | |
* Document for »About Section«: | ||
Record changed: 2023-12-20 |
Advertisement
More documents for Otsuka (Group)
- [1] Ionis Pharmaceuticals, Inc.. (12/18/23). "Press Release: Ionis Announces European Licensing Agreement with Otsuka for Donidalorsen in Hereditary Angioedema". Carlsbad, CA....
- [2] ERS Genomics Ltd.. (3/3/21). "Press Release: ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical". Dublin....
- [3] Beckley Psytech Ltd.. (2/23/21). "Press Release: Beckley Psytech Appoints Ex-pharma CEO as Chief Operating Officer"....
- [4] Life Sciences Partners (LSP). (3/10/20). "Press Release: LSP Closes Largest Ever European Life Sciences Fund at $600 Million". Amsterdam, Munich & Boston, MA....
- [5] Bicycle Therapeutics plc. (10/29/19). "Press Release: Bicycle Therapeutics Announces Appointment of Nigel Crockett, Ph.D., as Chief Business Officer". Cambridge & Boston, MA....
- [6] Healx Ltd.. (7/11/19). "Press Release: Dr Neil Thompson Appointed CSO of Healx to Spearhead Drug Discovery Expansion"....
- [7] LeadXPro AG. (6/3/19). "Press Release: LeadXPro and Astex Enter Strategic Partnership on Membrane Protein Strcuture Research". Cambridge & Villigen....
- [8] Taiho Ventures, LLC. (10/16/18). "Press Release: Taiho Ventures Expands Investment Pool to US$300 Million to Continue Quality Investments and Accelerate Open Innovation". Menlo Park, CA....
- [9] Thermo Fisher Scientific Inc.. (5/16/18). "Press Release: Thermo Fisher Scientific Installs First Glacios Cryo-Electron Microscope for Drug Discovery and Development". Hillsboro, OR....
- [10] H. Lundbeck A/S. (2/7/18). "Press Release: Lundbeck Delivers Its Best Financial Results Following 10% Revenue Growth and 117% Growth in Net Profit". Valby....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top